Last reviewed · How we verify
E2007 (perampanel)
Perampanel is a non-competitive AMPA receptor antagonist that reduces glutamate-mediated excitatory neurotransmission in the brain.
Perampanel is a non-competitive AMPA receptor antagonist that reduces glutamate-mediated excitatory neurotransmission in the brain. Used for Partial-onset seizures (adjunctive therapy), Generalized tonic-clonic seizures (adjunctive therapy).
At a glance
| Generic name | E2007 (perampanel) |
|---|---|
| Also known as | perampanel, Perampanel |
| Sponsor | Eisai Inc. |
| Drug class | AMPA receptor antagonist |
| Target | AMPA receptor (GluA1-GluA4) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Perampanel selectively blocks AMPA-type glutamate receptors on the neuronal cell membrane, which are key mediators of excitatory synaptic transmission. By antagonizing these receptors, it reduces excessive neuronal firing and seizure activity. This mechanism differs from other antiepileptic drugs and provides an alternative approach to seizure control.
Approved indications
- Partial-onset seizures (adjunctive therapy)
- Generalized tonic-clonic seizures (adjunctive therapy)
Common side effects
- Dizziness
- Somnolence
- Headache
- Fatigue
- Irritability
- Ataxia
- Aggression/behavioral changes
Key clinical trials
- A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy (PHASE2)
- An Extended Access Program (EAP) for Perampanel
- A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures (PHASE4)
- Effect of Perampanel on Peritumoral Hyperexcitability in HGG (PHASE1, PHASE2)
- Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy (PHASE2)
- A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures
- Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy (PHASE4)
- Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |